NDC 0078-0937

EGATEN

Triclabendazole

EGATEN is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Triclabendazole.

• Product ID: 0078-0937_1aa6cfc5-8131-45c3-9ec5-c112460fd176
• NDC: 0078-0937
• Product Type: Human Prescription Drug
• Proprietary Name: EGATEN
• Generic Name: Triclabendazole
• Dosage Form: Tablet
• Route of Administration: ORAL
• Marketing Start Date: 2019-02-13
• Marketing Category: NDA / NDA
• Application Number: NDA208711
• Labeler Name: Novartis Pharmaceuticals Corporation
• Substance Name: TRICLABENDAZOLE
• Active Ingredient Strength: 250 mg/1
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 0078-0937-91

4 TABLET in 1 BLISTER PACK (0078-0937-91)

• Marketing Start Date: 2019-02-13
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0078-0937-91 [00078093791]

EGATEN TABLET

• Marketing Category: NDA
• Application Number: NDA208711
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2019-02-13

Drug Details

Active Ingredients

Ingredient	Strength
TRICLABENDAZOLE	250 mg/1

OpenFDA Data

• SPL SET ID: 5552884e-10ea-450c-9658-d3d4f33c946e
• Manufacturer:
  • Novartis Pharmaceuticals Corporation
• UNII:
  • 4784C8E03O
• RxNorm Concept Unique ID - RxCUI:
  • 2118612
  • 2118606